TWiPO #11 ~ BuMel SIOP results and MIBG transplant with Dr Brian Weiss - a podcast by Solving Kids Cancer
from 2014-02-10T16:13:11
July
12, 2011
In this eleventh episode of "This Week in
Pediatric Oncology" hosts Dr. Tim Cripe and Dr. Lars Wagner discuss with
guest Dr. Brian Weiss (Cincinnati Children's Hospital) the implications of the
recent results comparing two chemotherapy combinations for transplant regimens in
children with high-risk neuroblastoma in Europe. The BuMel (busulfan,
melphalan) regimen resulted in better survival and lower toxicity than CEM
(carboplatin, etoposide, melphalan), a regimen used for transplant in the COG
for a decade.
This SIOP trial was one of the plenary
presentations at ASCO in June 2011. In this lively and informative discussion,
Dr. Brian Weiss explains the COG response to these results due to the
difference in induction regimens. The BuMel regimen will be used in the
upcoming MIBG frontline pilot that Dr. Weiss is leading as principal
investigator.
Dr. Weiss and TWiPO hosts also discussed the
recent paper Safety and efficacy of tandem (131) I-metaiodobenzylguanidine infusions
in relapsed/refractory neuroblastoma authored by Johnson et
al in Pediatr Blood Cancer. 2011 Apr 14
Please send questions and comments to
twipo@solvingkidscancer.org
Further episodes of This Week in Pediatric Oncology
Further podcasts by Solving Kids' Cancer
Website of Solving Kids' Cancer